2017;31((Suppl
[Published correction appears in JAMA
DOI: Published online: October 15, 2025 1 Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan 3 Kurinami Clinic, Kanzaki, Kumamoto, Japan 4 Division of Cardiovascular Medicine, Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan 5 Division of Preventive Cardiology, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto, Japan Corresponding author: Hideaki Jinnouchi
According to Health Canada data, spending on Ozempic increased from CAD $13.5 million in 2019 to CAD $227 million in 2021, with 36-74% of private insurance claims potentially from patients without diabetes seeking weight loss benefits
DrWS: All the literature and information that started on peptides really began with insulin
In contrast, incretin-based therapies, including GLP-1 receptor agonists (like semaglutide and dulaglutide) and the dual GIP/GLP-1 receptor agonist tirzepatide, do not cause glucosuria and therefore lack this specific mechanism for promoting fungal infections